​

Verastem (VSTM) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

VSTM Stock Forecast


Verastem (VSTM) stock forecast, based on 19 Wall Street analysts, predicts a 12-month average price target of $16.43, with a high of $22.00 and a low of $12.00. This represents a 64.30% increase from the last price of $10.00.

- $5 $10 $15 $20 $25 High: $22 Avg: $16.43 Low: $12 Last Closed Price: $10

VSTM Stock Rating


Verastem stock's rating consensus is Buy, based on 19 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 15 Buy (78.95%), 4 Hold (21.05%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 19 0 4 15 Strong Sell Sell Hold Buy Strong Buy

VSTM Price Target Upside V Benchmarks


TypeNameUpside
StockVerastem64.30%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends


1M3M12M
# Anlaysts3614
Avg Price Target$18.00$16.17$15.86
Last Closing Price$10.00$10.00$10.00
Upside/Downside80.00%61.70%58.60%
Ratings Trends

DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2619---10
Sep, 2618---9
Aug, 2618---9
Jul, 2618---9
Jun, 2618---9
Analyst Price Target Forecasts

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 15, 2026Industrial Alliance Securities$22.00$8.05173.29%120.00%
Oct 15, 2026Leonid TimashevRBC Capital$19.00$7.71146.43%90.00%
Oct 14, 2026Faisal KhurshidJefferies$13.00$7.7168.61%30.00%
Sep 14, 2026Andres MaldonadoH.C. Wainwright$18.00$7.32145.90%80.00%
Aug 10, 2026Mizuho Securities$13.00$6.5199.69%30.00%
Aug 07, 2026Guggenheim$12.00$5.91103.05%20.00%
Jul 07, 2026RBC Capital$14.00$4.46213.90%40.00%
Jun 24, 2026Leonid TimashevRBC Capital$15.00$4.33246.42%50.00%
Jun 23, 2026Jefferies$8.00$4.3285.19%-20.00%
May 08, 2026BTIG$18.00$5.66218.02%80.00%
Analyst Rating Forecasts

DateCompanyPrevious RatingNew RatingRating Change
Oct 16, 2026BenchmarkBuyBuyhold
Oct 15, 2026Alliance Global PartnersBuyBuyhold
Oct 15, 2026RBC CapitalOutperformOutperformhold
Oct 14, 2026JefferiesBuyBuyhold
Oct 08, 2026CitigroupBuyBuyhold
Oct 05, 2026BTIGBuyBuyhold
Oct 05, 2026H.C. WainwrightBuyBuyhold
Sep 28, 2026Cantor FitzgeraldOverweightOverweighthold
Sep 17, 2026Wolfe ResearchOutperforminitialise
Sep 14, 2026H.C. WainwrightBuyBuyhold

Financial Forecast


EPS Forecast

$-20 $-15 $-10 $-5 $0 $5 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-4.92$-4.57$-3.96$-3.66$-3.02---
Avg Forecast$-4.76$-4.71$-3.14$-3.03$-2.57$-1.56$-0.53$1.11
High Forecast$-2.07$-0.12$-3.14$-2.90$-2.20$0.34$3.83$3.55
Low Forecast$-12.20$-15.14$-3.15$-3.13$-2.84$-3.02$-4.79$0.03
Surprise %3.36%-2.97%26.11%20.79%17.51%---

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.05M$2.60M-$10.00M$30.91M---
Avg Forecast$1.47M$2.66M$5.93M$7.70M$22.94M$94.46M$199.00M$376.45M
High Forecast$3.24M$7.20M$16.01M$20.78M$36.20M$94.46M$537.11M$1.02B
Low Forecast$830.87K$668.98K$1.49M$1.93M$9.66M$94.46M$49.89M$94.38M
Surprise %39.72%-2.55%-29.87%34.75%---

Net Income Forecast

$-350M $-260M $-170M $-80M $10M $100M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-71.20M$-73.81M$-87.37M$-130.64M$-209.47M---
Avg Forecast$-104.98M$-103.90M$-69.34M$-66.52M$-55.51M$-29.63M$19.53M$24.37M
High Forecast$-45.68M$-2.75M$-69.16M$-63.97M$-48.46M$7.41M$84.36M$78.19M
Low Forecast$-269.12M$-333.99M$-69.53M$-69.06M$-62.55M$-66.67M$-105.59M$631.46K
Surprise %-32.18%-28.96%25.99%96.39%277.38%---

VSTM Forecast FAQ


Is Verastem stock a buy?

Verastem stock has a consensus rating of Buy, based on 19 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 15 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Verastem is a favorable investment for most analysts.

What is Verastem's price target?

Verastem's price target, set by 19 Wall Street analysts, averages $16.43 over the next 12 months. The price target range spans from $12 at the low end to $22 at the high end, suggesting a potential 64.30% change from the previous closing price of $10.

How does Verastem stock forecast compare to its benchmarks?

Verastem's stock forecast shows a 64.30% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Verastem over the past three months?

  • October 2026: 10.00% Strong Buy, 90.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 11.11% Strong Buy, 88.89% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 11.11% Strong Buy, 88.89% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Verastem’s EPS forecast?

Verastem's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.56, marking a -48.34% decrease from the reported $-3.02 in 2025. Estimates for the following years are $-0.53 in 2027, and $1.11 in 2028.

What is Verastem’s revenue forecast?

Verastem's average annual revenue forecast for its fiscal year ending in December 2026 is $94.46M, reflecting a 205.57% increase from the reported $30.91M in 2025. The forecast for 2027 is $199M, and $376.45M for 2028.

What is Verastem’s net income forecast?

Verastem's net income forecast for the fiscal year ending in December 2026 stands at $-29.633M, representing a -85.85% decrease from the reported $-209M in 2025. Projections indicate $19.53M in 2027, and $24.37M in 2028.